RxDoctor Payments DataLook up a doctor →

Stephanie Delgaudioriemann, MD

Neurology · Woodstock, GANPI 1306819743

Payments from drug & device makers

$167,108in general payments, 2019–2025

Across 1,326 payments — averaging $126.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$97K
  • Teva Pharmaceuticals USA, Inc.$38K
  • Lilly USA, LLC$5K
  • Lundbeck LLC$3K
  • Biogen$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • plus $20K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)269$96,554
Teva Pharmaceuticals USA, Inc.115$37,640
Lilly USA, LLC44$5,268
Lundbeck LLC38$3,395
Biogen109$2,302
E.r. Squibb & Sons, L.L.C.3$2,252
Livanova USA, Inc.6$1,759
UCB, Inc.74$1,757
Supernus Pharmaceuticals, Inc.19$1,273
Amgen(2 entities)69$1,202
Abbott9$1,161
Acadia Pharmaceuticals Inc46$909
Novartis54$864
SK Life Science, Inc.30$792
Pfizer34$767
AstraZeneca31$754
Bristol Myers Squibb13$734
Genentech USA, Inc.26$571
Argenx US, Inc.22$553
Neurelis, Inc.15$426
Eisai Inc.17$381
Amneal Pharmaceuticals LLC22$343
Neurocrine Biosciences, Inc.13$338
Avanir Pharmaceuticals, Inc.19$314
Greenwich Biosciences, Inc.5$301
EMD Serono, Inc.16$296
Banner Life Sciences, LLC10$288
MDD US Operations, LLC12$267
Upsher-smith Laboratories LLC18$265
Takeda Pharmaceuticals U.S.A., Inc.11$260
Arbor Pharmaceuticals, Inc.14$251
Biohaven Pharmaceutical Holding Company Ltd.14$233
Sumitomo Pharma America, Inc.9$228
Adamas Pharmaceuticals, Inc.11$226
Sanofi10$194
Otsuka America Pharmaceutical, Inc.8$169
Acorda Therapeutics, Inc8$154
Alfasigma USA, Inc.7$146
Nevro Corp.2$136
Scilex Pharmaceuticals Inc.6$129
Biohaven Pharmaceuticals, Inc.7$121
Jazz Pharmaceuticals Inc.5$107
Kyowa Kirin, Inc.6$103
Azurity Pharmaceuticals, Inc.5$94
Avion Pharmaceuticals4$78
Merz Pharmaceuticals, LLC3$75
CSL Behring3$70
Currax Pharmaceuticals LLC5$68
Grifols USA, LLC3$56
Axsome Therapeutics, Inc.3$52
Bausch Health US, LLC3$48
Endo Pharmaceuticals Inc.2$41
Forte Bio-pharma LLC2$39
Johnson & Johnson2$38
Corium, LLC2$36
Assertio Therapeutics, Inc.2$31
Alnylam Pharmaceuticals Inc.1$28
Impel Pharmaceuticals LLC2$27
Mallinckrodt Hospital Products Inc.1$26
Octapharma USA, Inc.1$23

How this compares

$167,108 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$444,336
Medicare patients
943
Services billed
13,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Woodstock

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →